Clinical Trial Update: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Erdafitinib versus standard therapies (vinflunine, docetaxel, or pembrolizumab) in advanced urothelial cancer with FGFR alterations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Erdafitinib (erdafitinib)
• Pembrolizumab (pembrolizumab)
• Vinflunine (vinflunine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urothelial Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-14